ResearcherUniversity of Occupational and Environmental Health JapanNo recent work listed
Toru Takeda
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2014: 1 paper · 2015: 1 paper
Papers 2
- The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-specific survival in pancreatic ductal aden… Co-author DOI 10.14670/hh-30.193↗
- The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ducta… Co-author DOI 10.1007/s13277-014-2328-8↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasuyuki Sasaguri · 2 shared papers, 2014–2015 · strength 0.08
- Paper The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-spe… DOI 10.14670/hh-30.193↗
- Paper The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened su… DOI 10.1007/s13277-014-2328-8↗
- Tomoko Kimura · 2 shared papers, 2014–2015 · strength 0.08
- Paper The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-spe… DOI 10.14670/hh-30.193↗
- Paper The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened su… DOI 10.1007/s13277-014-2328-8↗
- Sohsuke Yamada · 2 shared papers, 2014–2015 · strength 0.08
- Paper The combination of strong immunohistochemical mtTFA expression and a high survivin index predicts a shorter disease-spe… DOI 10.14670/hh-30.193↗
- Paper The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened su… DOI 10.1007/s13277-014-2328-8↗
- Zhi Li · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.